Abstract: The purpose of the present invention is to provide: a blood sample analysis method for determining diabetes complications in subjects with kidney damage on the basis of D- and L-amino acid content, from a blood sample; a method for examining diabetes complications; and a sample analysis system that outputs pathological information about diabetes complications. The purpose of this invention is achieved by using at least one amino acid selected from the group consisting of D-aspartic acid, D-proline, L-glutamine, and L-isoleucine, in order to determine diabetes complications.

Abstract: The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

Abstract: [Problem] To provide a fluorescence detection apparatus that is capable of simultaneously detecting a plurality of analyte components contained at different concentrations with a wide measurement range. [Solution] A fluorescence detection apparatus 100 includes a cell 110 into which an analyte of a sample is introduced, a light source 130 that irradiates excitation light on the analyte in the cell; a first detector 52 that detects fluorescence generated from the analyte after the excitation light has been irradiated on the analyte, and a second detector 53 that detects the fluorescence generated from the analyte after the excitation light has been irradiated on the analyte. The second detector detects the fluorescence with a measurement range that is different from the measurement range of the first detector, and the first detector and second detector detect the fluorescence simultaneously.

Abstract: The apparatus for analyzing a disease sample according to the present invention includes: a member for separating and quantitatively determining an amino acid stereoisomer in a biological material from a subject; a member for obtaining a disease state index value through a calculation by substituting the amount of the amino acid stereoisomer into a discriminant equation; and a member for outputting disease state information on the subject on the basis of the disease state index value. The method for analyzing a disease sample according to the present invention includes: a step of measuring the amount of amino acid stereoisomers in a biological material from a subject; a step of obtaining a disease state index value through a calculation by substituting the amount of the amino acid stereoisomers into a discriminant equation; and the like.

Abstract: The present invention addresses the problem of developing an analytical method which makes it possible to diagnose early or mild renal disorders. The method is based on calculating a disease-state index value for renal disorders on the basis of the quantities of D-form and/or L-form amino acids, from feces or intestinal content. By comparing the disease-state index value with a threshold value determined from the disease-state index values of a renal failure patient group and a healthy subject group, it is possible to diagnose a mild renal disorder patient group.

Abstract: The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.

Abstract: A chiral analysis method of a bound amino acid includes a step of hydrolyzing a bound amino acid using a deuterium chloride-deuterium oxide solution and/or deuterium oxide; a step of separating, by chiral separation, a D-form and an L-form of an amino acid generated by the hydrolyzation; a step of generating fragments from the separated amino acid; and a step of selecting and analyzing a predetermined fragment that contains an ? carbon and does not contain a side chain from the generated fragments, by mass spectrometry.

Abstract: The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.

Abstract: The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.

Abstract: Disclosed is a compound represented by chemical formula (1): or chemical formula (2):

Abstract: The present invention addresses the problem of identifying a biomarker of renal failure, said biomarker being available from urine or blood, and fluctuating from an early stage than glomerular filtration rate and serum creatinine level, and thus developing a technique for diagnosing early stage kidney failure. A method for analyzing the blood, plasma, serum or urine of a renal failure suspected subject comprises a step of measuring the concentration of a pair of D-form and L-form of at least one amino acid selected from the amino acid group consisting of [D-serine] and [L-serine], etc., contained in the blood, plasma, serum or urine of the subject, and calculating, as an pathological index of the subject, the ratio of the D-form concentration to the L-form concentration or the percentage of the D-form concentration relative to the total concentration of the D-form and L-form.

Abstract: An embodiment of the present invention is a separating agent wherein a group represented by a chemical formula of: or a group represented by a chemical formula of: is introduced on a surface thereof.

Abstract: Disclosed is a compound represented by chemical formula (1): or chemical formula (2):

Abstract: Disclosed is a compound represented by chemical formula (1): or chemical formula (2):

Abstract: A method for quantitatively analyzing cysteine and cysteine includes a first step of adding a methyl-sulfurating agent to a sample that includes cysteine and cystine to obtain a methyl-sulfurated cysteine, a second step of adding a derivatizing agent to the methyl-sulfurated cysteine and the cystine to obtain a cysteine derivative and a cystine derivative, respectively, and a third step of quantifying the cysteine derivative and the cystine derivative.

Abstract: The apparatus for analyzing a disease sample according to the present invention includes: a member for separating and quantitatively determining an amino acid stereoisomer in a biological material from a subject; a member for obtaining a disease state index value through a calculation by substituting the amount of the amino acid stereoisomer into a discriminant equation; and a member for outputting disease state information on the subject on the basis of the disease state index value. The method for analyzing a disease sample according to the present invention includes: a step of measuring the amount of amino acid stereoisomers in a biological material from a subject; a step of obtaining a disease state index value through a calculation by substituting the amount of the amino acid stereoisomers into a discriminant equation; and the like.

Abstract: Disclosed is a compound represented by chemical formula (1): or chemical formula (2):

Abstract: A method for quantitatively analyzing cysteine and cysteine includes a first step of adding a methyl-sulfurating agent to a sample that includes cysteine and cystine to obtain a methyl-sulfurated cysteine, a second step of adding a derivatizing agent to the methyl-sulfurated cysteine and the cystine to obtain a cysteine derivative and a cystine derivative, respectively, and a third step of quantifying the cysteine derivative and the cystine derivative.

Abstract: Disclosed is a stable and safe antioxidant composition which can be used routinely. Specifically disclosed is an antioxidant composition which contains one or more compounds selected from the group consisting of D-aspartic acid, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include, but is not limited to, fine wrinkles, a rough skin, a dry skin, a skin cancer, a skin allergy, an inflammation of the skin and a photosensitive dermatosis. The composition may be used for an external preparation for the skin, a food, and a pharmaceutical product for cataract.

Abstract: An embodiment of the present invention is a separating agent wherein a group represented by a chemical formula of: or a group represented by a chemical formula of: is introduced on a surface thereof.